Overview
Zinc supplementation addresses the functional zinc deficiency in ASD caused by toxic metal displacement at binding sites. Lead, mercury, and cadmium enter cells via calcium channels and displace zinc from critical enzymes and structural proteins (Primitive 3: mis-metallation).
Mechanism
- Competitive displacement: Supplemental Zn2+ competes with Pb2+, Hg2+, and Cd2+ for metallothionein and enzyme binding sites (Primitive 4: metal dependencies as Achilles' heels)
- Barrier restoration: Zinc-dependent tight junction proteins (claudins, occludin) are restored, reducing intestinal permeability
- Immune modulation: Zinc is required for thymulin activity and T-cell maturation
- Metallothionein induction: Zinc supplementation upregulates metallothionein, which sequesters toxic metals
Clinical Evidence
- Cu/Zn ratio normalized in ASD children with GI symptoms after supplementation
- Zinc deficiency prevalence is elevated across multiple ASD cohorts
- ASD+GI subgroup shows the strongest response, consistent with barrier dysfunction as a mediating mechanism
Clinical Considerations
- Monitor Cu/Zn ratio to avoid copper depletion with prolonged supplementation
- ASD+GI phenotype may be the best responder subgroup
- Combine with toxic metal exposure reduction for maximum benefit